GlobeNewsWire
22 Sept 2026, 23:21 UTC · 1h ago
Verdict
Headline takes no side. We score EYPT −1.00 across two claims — strongly bearish.
−1.00strongly bearish
More negative than 95% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish · 1 new · 1 priced in
EyePoint's LUGANO Phase 3 trial for DURAVYU failed to meet its primary endpoint of change from baseline in best corrected visual acuity versus aflibercept.
Priced inpress release dated August 17, 2026
So whatThe 66.98% price drop on August 17 indicates the market has already wiped out the valuation associated with this specific drug's path to approval.
More negative than 99% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Pomerantz Law Firm is investigating whether EyePoint and its officers engaged in securities fraud or unlawful business practices.
Newpress release dated Sept. 22, 2026
So whatLegal proceedings can lead to significant settlement costs or distractions for management over the next 12-24 months.
More negative than 70% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a class action investigation for potential securities fraud following a failed Phase 3 clinical trial and a massive stock price drop.
More negative than 86% of ticker scores this week
A class action lawsuit has been filed against the company.
More negative than 86% of ticker scores this week
A class action lawsuit has been filed against the company.
More positive than 51% of ticker scores this week
The article notes that a competitor's drug failed to meet its endpoint against Regeneron's Eylea.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1h ago
—
EYPT hasn't traded since this ran. Last close $4.07 (Sep 22); the reaction starts at the next open.
EYPT chart →